Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction of Radiotherapy Efficacy in TNBC
NCT06418126Active, not recruiting
- Sponsor
- Centre Paul Strauss
- Start
- Jan 2024
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by Centre Paul Strauss. Primary endpoint: Predictive value of recurrence associated with the appearance of inflammatory cytokines at 5 years. Started Jan 2024; status: active, not recruiting.
Beyond the preview
Go deeper on NCT06418126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06418126.